Heritability, Genetics, and Counseling in hEDS

Hypermobile Ehlers-Danlos syndrome (hEDS) is widely recognized as a heritable connective tissue disorder, yet it remains unique among the Ehlers-Danlos syndromes in that its precise genetic cause has not been identified. Unlike other EDS subtypes that can be confirmed through molecular testing, hEDS continues to be diagnosed using clinical criteria based on physical findings, symptom patterns, and family history. This absence of a definitive genetic test has contributed to confusion, delayed diagnosis, and emotional distress for many individuals and families, even as evidence of heritability has steadily accumulated.

For many years, the inability to identify a single causative gene led to uncertainty about the biological basis of hEDS. Some clinicians questioned whether it represented a distinct genetic condition or a heterogeneous group of overlapping disorders. However, newer research has begun to clarify this picture. Rather than reflecting a lack of genetic cause, hEDS appears to be driven by genetic complexity. Current evidence supports the view that hEDS is a polygenic condition, meaning that it is influenced by the combined effects of many genes, each contributing a small amount of risk rather than a single dominant mutation. In addition, hEDS appears to be multisystem, affecting multiple biological systems rather than only connective tissue. This evolving understanding represents a major shift in how hEDS is conceptualized and studied and helps explain its wide clinical variability.

Inheritance Pattern and Family History

Clinical observation and family studies consistently support an autosomal dominant inheritance pattern in most individuals with hEDS. Autosomal dominant means that inheriting one copy of the underlying genetic susceptibility from either parent is sufficient to increase the likelihood of developing the condition. In practical terms, each child of an affected individual is estimated to have approximately a 50 percent chance of inheriting the predisposition. This estimate is based on observed family patterns rather than molecular confirmation, as no definitive genetic marker currently exists.

In many families, at least one parent is later recognized to have features of hEDS that were previously undiagnosed or overlooked. These may include joint hypermobility, frequent sprains or dislocations, chronic musculoskeletal pain, easy bruising, soft or fragile skin, gastrointestinal symptoms, or autonomic dysfunction. In earlier generations, such features were often normalized, minimized, or attributed to aging, anxiety, injury, or lifestyle rather than recognized as manifestations of a heritable connective tissue disorder.

This pattern reflects two important genetic concepts. The first is variable expressivity, meaning that individuals who share the same genetic susceptibility may experience very different symptoms or degrees of severity. The second is incomplete penetrance, meaning that not everyone who inherits the genetic predisposition will develop symptoms that clearly meet diagnostic criteria. Together, these features help explain why hEDS can appear to “skip” generations or present very differently among affected relatives.

Although hEDS most commonly runs in families, some individuals report no known family history. These cases may reflect subtle or undiagnosed manifestations in relatives, incomplete historical information, or, less commonly, new genetic changes that arise spontaneously in the affected individual. Available evidence suggests that truly sporadic cases are uncommon and that inherited susceptibility remains the dominant pattern.

Hypermobility spectrum disorder (HSD) is frequently observed in families with hEDS and may represent a milder or partial expression of the same underlying genetic susceptibility. This familial clustering supports the hypothesis that hEDS and HSD exist along a shared heritable continuum, even though HSD is not formally classified as an EDS subtype. At present, both remain clinical diagnoses without definitive genetic confirmation.

Why There Is No Single Genetic Test for hEDS

Despite decades of investigation, researchers have not identified a single gene mutation that explains most cases of hEDS. Large studies using whole-exome sequencing, whole-genome sequencing, and targeted gene panels have repeatedly failed to identify a consistent pathogenic variant across affected individuals. While a small number of candidate genes have been proposed over time, these account for only a minority of cases and do not provide a reliable or generalizable diagnostic tool.

Recent research has clarified why these approaches have been unsuccessful. Instead of a single causative mutation, hEDS appears to arise from the cumulative effects of multiple genetic variants spread across different biological systems. A new and groundbreaking study published in 2025–2026 used advanced computational and machine-learning methods to analyze whole-exome data from individuals with hEDS and their unaffected relatives. This study identified distinctive patterns of genetic variation affecting three major functional domains: connective tissue structure, immune system regulation, and mitochondrial energy production. This finding was reported in the study “Multisystem genetic changes drive hypermobile EDS" in the Feb. 28, 2026 publication of Genes.

The connective tissue domain includes genes involved in collagen organization and tissue integrity, which may help explain joint instability, frequent injuries, poor wound healing, and chronic pain. The immune system domain includes genes involved in immune signaling and regulation, which may help explain the high rates of immune-related conditions seen in hEDS, such as allergic-type reactions, inflammation, and mast cell–related symptoms like those seen in mast cell activation syndrome (MCAS). The mitochondrial energy domain includes genes involved in how cells produce and use energy, which may contribute to fatigue, exercise intolerance, autonomic symptoms, and difficulty recovering from physical or cognitive exertion.

Together, these findings provide strong biological evidence that hEDS is a genuine genetic condition with a complex, multisystem basis. They also help explain why hEDS affects far more than joints alone and why individuals with similar degrees of hypermobility can have very different overall health profiles.

Importantly, this research reframes the question from “What is the gene for hEDS?” to “What combination of genetic factors increases susceptibility to hEDS?” This shift has significant implications for future research, diagnosis, and counseling.

Implications for Genetic Counseling

In the absence of a definitive genetic test, genetic counseling for hEDS relies on clinical features, family history, and empiric risk estimates rather than molecular confirmation. Counselors typically explain that hEDS most often behaves as an autosomal dominant condition with variable expressivity and incomplete penetrance. While the estimated recurrence risk for children of an affected parent is approximately 50 percent, the presence, severity, and specific manifestations of symptoms cannot be predicted.

Predictive testing for asymptomatic individuals is not currently available. Predictive testing refers to testing a person without symptoms to determine whether they will develop a condition in the future. In children, especially those with mild symptoms, diagnosis is often deferred until adolescence or early adulthood, when joint hypermobility and associated features can be more reliably distinguished from normal developmental flexibility. This cautious approach helps avoid both overdiagnosis and premature reassurance.

In reproductive counseling, individuals with hEDS are informed that prenatal testing and preimplantation genetic diagnosis are not currently possible, due to the absence of a defined genetic marker. Counseling therefore focuses on education, realistic expectations, and discussion of variability rather than genetic prevention. Prospective parents are encouraged to consider both the potential challenges and the wide range of outcomes seen in affected individuals.

Psychological and Social Impact of Diagnostic Uncertainty

The lack of a molecular diagnostic test has profound psychological and social consequences for many people with hEDS. Individuals often endure years or decades of symptoms before receiving a diagnosis, during which their experiences may be dismissed, minimized, or attributed to psychological causes. This prolonged uncertainty can undermine trust in healthcare systems and contribute to feelings of self-doubt and invalidation.

Research and clinical experience consistently show higher rates of anxiety, depression, and social isolation among people with hEDS, particularly when they encounter skepticism from healthcare providers. These effects can be especially pronounced in children and adolescents, where diagnostic ambiguity may delay access to appropriate accommodations, therapy, and support.

Clinical Challenges for Healthcare Providers

For clinicians, diagnosing hEDS requires careful clinical assessment, application of diagnostic criteria, and exclusion of other heritable connective tissue disorders with known genetic causes. This process can be particularly challenging in individuals with subtle findings, overlapping conditions, or multisystem symptoms that do not fit neatly into traditional frameworks.

The absence of a genetic test can also create practical barriers to care. In some healthcare systems, access to specialized services or insurance coverage depends on molecular confirmation, placing individuals with hEDS at a disadvantage despite significant functional impairment.

Research and the Future of Diagnosis

Current genetic research represents a turning point in the field of hEDS. Rather than continuing to search exclusively for a single causative gene, newer studies focus on identifying genetic patterns, biological pathways, and molecular signatures associated with the condition. The recent study identifying multisystem genetic variation in hEDS marks a major advance, providing long-awaited biological validation and a clearer direction for future work.

As this research progresses, future diagnostic approaches may incorporate genetic risk profiles, biomarkers, or integrated clinical-genetic models rather than relying on a single mutation. Such advances could dramatically improve diagnostic accuracy, reduce stigma, and expand access to care.

Summary

Hypermobile Ehlers-Danlos syndrome is a heritable connective tissue disorder that most commonly follows an autosomal dominant inheritance pattern with variable expressivity and incomplete penetrance. Most individuals diagnosed with hEDS have at least one affected family member, though symptoms may vary widely in severity and presentation.

Although no single causative gene has been identified, new research clearly demonstrates that hEDS has a complex genetic basis involving multiple biological systems. This polygenic and multisystem model explains the broad clinical variability seen in hEDS and distinguishes it from other genetically defined EDS subtypes.

The absence of a molecular diagnostic test continues to complicate diagnosis, counseling, reproductive planning, and access to care, while also contributing to psychological burden and medical invalidation. However, recent groundbreaking genetic research provides strong biological evidence for hEDS and reshapes the future of diagnosis and understanding. Until definitive diagnostic tools are available, careful clinical assessment, informed counseling, and comprehensive multidisciplinary care remain essential.